Ensysce Biosciences (ENSCW) Research & Development (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Research & Development of $3.0 million for Q3 2025, up 74.78% year-over-year from $1.7 million in Q3 2024, and up 53.63% quarter-over-quarter from $1.9 million in Q2 2025.
Ensysce Biosciences (ENSCW) Research & Development (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Research & Development data on file, last reported at $3.0 million in Q3 2025.
- Research & Development for Q3 2025 came in at $3.0 million, up 74.78% year-over-year; the trailing twelve-month figure through Sep 2025 was $10.6 million (up 87.03% YoY), and the FY2024 annual result was $7.2 million, down 4.85% from the prior year.
- Research & Development climbed to $3.0 million in Q3 2025 per ENSCW's latest filing, from $1.9 million in the prior quarter.
- Over five years, Research & Development peaked at $6.4 million in Q4 2022 and troughed at $284378.0 in Q1 2021.
- A 5-year average of $2.4 million and a median of $1.9 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development soared 1046.61% in 2022, then sank 69.05% in 2023.
- A 5-year view of Research & Development shows it stood at $2.2 million in 2021, then surged by 194.44% to $6.4 million in 2022, then plunged by 65.34% to $2.2 million in 2023, then soared by 70.31% to $3.8 million in 2024, then fell by 22.29% to $3.0 million in 2025.
- Business Quant data shows ENSCW's Research & Development at $3.0 million in Q3 2025, $1.9 million in Q2 2025, and $1.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.95 Mn |
| Jun 30, 2025 | 1.92 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 947,229.00 |
| Mar 31, 2024 | 778,904.00 |
| Dec 31, 2023 | 2.23 Mn |
| Sep 30, 2023 | 1.91 Mn |
| Jun 30, 2023 | 1.64 Mn |
| Mar 31, 2023 | 1.80 Mn |
| Dec 31, 2022 | 6.44 Mn |
| Sep 30, 2022 | 4.76 Mn |
| Jun 30, 2022 | 5.31 Mn |
| Mar 31, 2022 | 3.14 Mn |
| Dec 31, 2021 | 2.19 Mn |
| Sep 30, 2021 | 1.71 Mn |
| Jun 30, 2021 | 463,219.00 |
| Mar 31, 2021 | 284,378.00 |
| Dec 31, 2020 | 1.25 Mn |